Sign In
Buy GSK
$51.53
+0.0200 (+0.0388%)
At Close: Aug 04, 2026
GSK NDA for Myelofibrosis Candidate Gets FDA Acceptance
12:46pm, Thursday, 18'th Aug 2022 Zacks Investment Research
GSK's NDA for momelotinib for treating myelofibrosis was based on data from key phase III studies, including the pivotal MOMENTUM study.
GSK NDA for Myelofibrosis Candidate Gets FDA Acceptance
09:47am, Thursday, 18'th Aug 2022
GSK's NDA for momelotinib for treating myelofibrosis was based on data from key phase III studies, including the pivotal MOMENTUM study.
Plaintiff in first Zantac lawsuit set for trial drops case
02:54pm, Wednesday, 17'th Aug 2022
The plaintiff in the first lawsuit over the heartburn drug Zantac scheduled to go to trial has agreed to drop his case, according to his attorney and drugmakers named as defendants.
Recent Stock Purchase August 2022
02:40pm, Wednesday, 17'th Aug 2022
This month I deployed more cash than last month totaling almost $2,000. People like to talk about crypto volatility but the market in recent months has plenty of examples of wild price swings too.
Zantac lawsuit drop ‘not as significant as it appears' for GSK stock, analysts say
07:09am, Wednesday, 17'th Aug 2022
The withdrawal of the plaintiff in the first lawsuit over GSK's heartburn drug Zantac may not be “as significant as it first appears” for the company's shares, say analysts from RBC Capital Market
GSK: First Zantac case plaintiff drops lawsuit
03:19am, Wednesday, 17'th Aug 2022
The first of the legal cases against companies that sold the heartburn drug Zantac ended before it started after the plaintiff dropped his case. Joseph Bayer, who brought the action against GSK PLC (L
Gilead (GILD) Announces Positive Data on Breast Cancer Drug
05:10pm, Tuesday, 16'th Aug 2022 Zacks Investment Research
Gilead (GILD) breast cancer drug Trodelvy improves overall survival in pre-treated HR+/HER2- metastatic breast cancer patients. The company will also acquire the remaining rights to the drug.
Plaintiff drops suit in first Zantac trial
04:45pm, Tuesday, 16'th Aug 2022
Yahoo Finance health care correspondent Anjalee Khemlani details how the first case against pharmaceutical company GSK over its Zantac derivative was voluntarily dismissed.
Potential Lawsuits Causing Zantac Manufacturers Heartburn
04:10pm, Monday, 15'th Aug 2022
Concerns over potential liability for a medication purported to cause cancer sliced billions off the value of several manufacturers of the drug in the past week. But were the cuts too deep?
Bert's July Dividend Income Summary | Dividend Investing 2022
04:28am, Monday, 15'th Aug 2022
Our total dividend income decreased from $771.96 received in July 2021. Canadian Imperial takes the crown for the largest dividend payment of the month.
GSK defends Zantac ahead of trials that have wiped off $44 billion from leading drugmakers
07:24pm, Friday, 12'th Aug 2022 MarketWatch
GSK on Friday put out a statement saying there's no link between a withdrawn heartburn medication and cancer, helping to stem a slide in its stock that has wiped out billions of dollars in valuation f
Do I Need to Get A Polio Vaccine? New York Sewer Discovery Triggers Fears About Paralysis-Inducing Virus
07:19pm, Friday, 12'th Aug 2022 Benzinga
New York officials have detected polio in the city's wastewater, suggesting the virus has been circulating in the local area.
What Happened? On Friday, New York State Health Commissioner Dr. Mary Bass
PFE, GSK & Other Pharma Stocks Hit by Zantac Litigation
07:07pm, Friday, 12'th Aug 2022 Zacks Investment Research
Big pharma stocks, such as Glaxo (GSK), Sanofi (SNY), Pfizer (PFE) and Consumer stock Haleon (HLN), decline due to the litigation surrounding the heartburn drug Zantac (ranitidine).
PFE, GSK & Other Pharma Stocks Hit by Zantac Litigation
04:33pm, Friday, 12'th Aug 2022
Big pharma stocks, such as Glaxo (GSK), Sanofi (SNY), Pfizer (PFE) and Consumer stock Haleon (HLN), decline due to the litigation surrounding the heartburn drug Zantac (ranitidine).
Pharma companies see sales slump amid ongoing Zantac litigation
04:22pm, Friday, 12'th Aug 2022
Yahoo Finance health care reporter Anjalee Khemlani looks at which pharmaceutical stocks are being affected by litigation surrounding alleged carcinogenic materials in Zantac derivatives.
